New in Leukemia Journal : Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors nature.com/articles/s4137… #leusm

Overt and covert genetic causes of pediatric acute lymphoblastic leukemia | Leukemia nature.com/articles/s4137…

Prognostic scoring systems in chronic myeloid leukaemia | Leukemia nature.com/articles/s4137…

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia nature.com/articles/s4137…

A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells | Leukemia nature.com/articles/s4137…

Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia. @mayomyeloma Leukemia nature.com/articles/s4137…

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase European Hematology Association Andreas Hochhaus #EHA2025 #leusm hubs.li/Q03s5k0C0

Mit Mut für Freiheit und demokratische Grundrechte. Vor 72 Jahren, am 17. Juni 1953, gingen Hunderttausende Menschen in der DDR gegen die Unterdrückung des SED-Regimes auf die Straße. Wir erinnern heute an die Tapferkeit und den Mut dieser Menschen. Sie mahnen uns, dass Freiheit

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia nature.com/articles/s4137…

Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma | Leukemia ⁦Vincent Rajkumar⁩ nature.com/articles/s4137…

Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA Leukemia Journal open access. nature.com/articles/s4137…

Just published: On behalf of the European LeukemiaNet, an international expert panel led presented the 2025 update of the management recommendations of chronic myeloid leukemia #CML in the journal LEUKEMIA Leukemia Journal open access. nature.com/articles/s4137…

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia nature.com/articles/s4137…

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera | Leukemia nature.com/articles/s4137…

A one stop shop for the current risk stratification schema in plasma cell disorders! As always, thank you for being so generous with your time Vincent Rajkumar! Absolutely wonderful experience learning the art of scientific communication from the very best! #mmsm #bookmark

📣#ESHCML2025 PROGRAM HIGHLIGHT: 3 MEET THE EXPERT SESSIONS! Learn more & register here➡bit.ly/3ZQWwEa ESH-#iCMLf 27th John Goldman Conference on #CMLsm Chairs: Jorge Cortes MD Tim Hughes Daniela S. Krause #ESHCONFERENCES International CML Foundation

Join leading minds in CML care and research at the 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, held October 10–12 in beautiful Estoril, Portugal. 📍 Estoril, Portugal 🗓️ October 10–12, 2025 🔗 buff.ly/1Qtgp5R

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings Leukemia Journal nature.com/articles/s4137…

#ESHCML2025: THE PRELIMINARY PROGRAM IS AVAILABLE Read it now & register➡bit.ly/3ZQWwEa ESH-#iCMLf 27th John Goldman Conference on #CMLsm Oct. 10-12, 2025 in Estoril, Portugal Chairs: Jorge Cortes MD Tim Hughes Daniela S. Krause #ESHCONFERENCES International CML Foundation #Haematology #CMLsm